An Eight-Week, Multicenter, Double-Blind, Placebo- and Paroxetine-Controlled Study Evaluating the Efficacy and Tolerability of Two Fixed Doses of SSR149415 (250 mg Bid and 100 mg Bid) in Outpatients With Generalized Anxiety Disorder.

Trial Profile

An Eight-Week, Multicenter, Double-Blind, Placebo- and Paroxetine-Controlled Study Evaluating the Efficacy and Tolerability of Two Fixed Doses of SSR149415 (250 mg Bid and 100 mg Bid) in Outpatients With Generalized Anxiety Disorder.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 May 2016

At a glance

  • Drugs Paroxetine; SSR 149415
  • Indications Generalised anxiety disorder
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 25 Jul 2011 Actual initiation date changed from Sep 2006 to Aug 2006 as reported by ClinicalTrials.gov.
    • 25 Nov 2008 Status changed from active, no longer recruiting to completed.
    • 14 Nov 2008 Actual end date added, as reported by clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top